Geneva, Nov. 3 -- International Clinical Trials Registry received information related to the study (NCT07220824) titled 'A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting' on Oct. 22.
Study Type: Observational
Primary Sponsor: Janssen Research & Development, LLC
Condition:
Arthritis, Psoriatic
Recruitment Status: Not recruiting
Date of First Enrollment: October 31, 2025
Target Sample Size: 200
To know more, visit https://clinicaltrials.gov/study/NCT07220824
Disclaimer: Curated by HT Syndication....